Date: 2014-11-21
Type of information: Exercise of an option agreement
Compound: oral first-in-class treatments of allergic diseases based on ActoBiotics™
Company: Stallergenes (France) Actogenix (Belgium)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: development
Action mechanism: ActoBiotics™ consist of genetically engineered lactic acid bacteria genetically engineered to synthesize and secrete therapeutic proteins and peptides in situ. They are delivered to patients via oral administration instead of injection, and allo local mucosal delivery of recombinant allergens, expressed and secreted at the mucosa. This first-in-class technology modulates the immune response to allergens and could significantly increase the efficacy of allergen immunotherapy treatments, with a reduced dose of allergens. They are formulated as simple oral capsules, resulting in greater patient compliance and reduced treatment cost.
Disease: allergic diseases
Details: * On December 2, 2013, Stallergenes and ActoGeniX have announced that they have entered into an agreement for the development of innovative first-in-class treatments of allergic diseases. Under the terms of this agreement, ActoGeniX will be responsible for the creation of ActoBiotics™expressing and secreting a range of allergens. ActoGeniX will deliver to Stallergenes clinical product candidates that express a set of predefined allergens. Upon exercise of its option, Stallergenes will have full development and exclusive worldwide commercialization rights on the product candidates, and ActoGeniX will be eligible to receive upfront, preclinical, clinical, regulatory and commercial milestone payments totaling up to € 75 million per allergen, as well as tiered royalties on the future product’s net sales.
Stallergenes currently holds an option to different groups of allergens amongst the most prevalent and with the highest unmet medical needs. Further details are not disclosed.
Financial terms: ActoGeniX will be eligible to receive upfront, preclinical, clinical, regulatory and commercial milestone payments totaling up to € 75 million per allergen, as well as tiered royalties on the future product’s net sales.
Latest news: * On November 20, 2014, Stallergènes announced that it has exercised the option to pursue the exclusive development of an innovative new class of oral allergy treatments in partnership with ActoGeniX in accordance with the contract signed in December 2013. The collaboration centers on the development of a novel treatment approach based on allergen-specific tolerance through innovative delivery of allergens expressed and secreted by the allergen-secreting L.lactis bacteria. Stallergenes and ActoGeniX have successfully conducted a Proof of Principle (PoP) study in preclinical models to validate the application of ActoGeniX's technology to allergens.
On December 2, 2013, the companies entered into an agreement for the development of innovative first-in-class treatments of allergic diseases. Under the terms of this agreement, ActoGeniX is responsible for the creation of clinical product candidates based on the application of ActoBiotics™ genetically engineered lactic acid bacteria to a set of allergens defined by Stallergenes.
